# SCG5

## Overview
SCG5 is a gene that encodes the protein secretogranin V, which is a member of the granin family of proteins. Secretogranin V functions primarily as a molecular chaperone within the secretory pathway of neuroendocrine cells, where it plays a critical role in the processing and maturation of prohormones and neuropeptides. This protein is particularly important for the activation and function of prohormone convertase 2 (PCSK2), an enzyme essential for converting prohormones into their active forms. Secretogranin V's involvement in the regulation of body weight, glucose homeostasis, and immune responses highlights its significance in various physiological processes and disease states, including metabolic disorders, autoimmune diabetes, and certain cancers (Suckale2010The; Farber2008Overexpression; CorralPujol2023NOD).

## Function
SCG5, also known as secretogranin V, is a protein that plays a crucial role in the processing of prohormones and neuropeptides within the secretory pathway of neuroendocrine cells. It functions primarily as a molecular chaperone, facilitating the proper folding and sorting of peptide precursors, which is essential for the maturation and secretion of bioactive hormones and neurotransmitters (Suckale2010The). SCG5 is active in the secretory granules, where it influences the enzymatic activity of prohormone convertase 2 (PCSK2), a key enzyme involved in the conversion of prohormones into their active forms (Farber2008Overexpression).

The protein is involved in the regulation of body weight and glucose homeostasis, as its overexpression has been shown to increase PCSK2 activity, which is linked to the processing of peptides that regulate these physiological processes (Farber2008Overexpression). SCG5's role in the secretory pathway is critical for maintaining the balance of hormone secretion, and its dysfunction can lead to metabolic disorders. The protein's activity is modulated by genetic variations near its locus, which can significantly affect its expression levels and, consequently, its physiological outcomes (Farber2008Overexpression).

## Clinical Significance
Alterations in the expression of the SCG5 gene, also known as secretogranin V, have been implicated in various diseases and conditions. In the context of body weight regulation, increased expression of SCG5 is associated with decreased body weight and obesity in mouse models. This is thought to be due to its role in increasing the enzymatic activity of prohormone convertase 2 (PCSK2), although the exact mechanism remains unclear (Farber2008Overexpression).

In autoimmune diabetes (T1D), SCG5 is overexpressed in the dorsal root ganglia and white blood cells of NOD mice, suggesting a role in altered neuropeptide processing and signaling. This overexpression may contribute to neurodegenerative processes and diabetic neuropathy, potentially triggering autoimmune responses (CorralPujol2023NOD).

In cancer, SCG5 expression has been linked to pancreatic adenocarcinoma (PAAD), where higher expression levels are associated with improved survival outcomes. This suggests a potential protective role against cancer progression (Kołat2022Prognostic). SCG5 is also overexpressed in certain neuroendocrine tumors, indicating its involvement in tumor pathophysiology (Cassarino2018Gene).

## Interactions
SCG5, also known as secretogranin V, is a protein that plays a significant role in the regulation of prohormone convertases, particularly PC2. SCG5 acts as a molecular chaperone for PC2, facilitating its activation and function in neuroendocrine cells. This interaction is crucial for the biosynthesis of peptide hormones and neuropeptides, as SCG5 helps in the proper folding and activation of PC2, which is involved in the processing of these peptides (Suckale2010The; Bartolomucci2011The).

The 7B2 protein, encoded by SCG5, contains a C-terminal peptide that acts as an inhibitor of PC2's catalytic activity, highlighting its regulatory role in modulating PC2 function (Bartolomucci2011The). Disruption of the SCG5 gene in mice results in a lack of PC2 activity, leading to severe metabolic and endocrine abnormalities, such as Cushing's syndrome, due to pituitary ACTH hypersecretion (Bartolomucci2011The).

SCG5 is also involved in the immune response associated with diabetes. Peptides derived from SCG5 are targeted by CD8+ T cells, indicating its role in autoimmune processes. These peptides are part of the autoimmune islet infiltrates in NOD mice and humans, contributing to the pathogenesis of diabetes (Azoury2020Peptides).


## References


[1. (Suckale2010The) Jakob Suckale and Michele Solimena. The insulin secretory granule as a signaling hub. Trends in Endocrinology &amp; Metabolism, 21(10):599–609, October 2010. URL: http://dx.doi.org/10.1016/j.tem.2010.06.003, doi:10.1016/j.tem.2010.06.003. This article has 150 citations.](https://doi.org/10.1016/j.tem.2010.06.003)

[2. (Bartolomucci2011The) Alessandro Bartolomucci, Roberta Possenti, Sushil K. Mahata, Reiner Fischer-Colbrie, Y. Peng Loh, and Stephen R. J. Salton. The extended granin family: structure, function, and biomedical implications. Endocrine Reviews, 32(6):755–797, August 2011. URL: http://dx.doi.org/10.1210/er.2010-0027, doi:10.1210/er.2010-0027. This article has 254 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/er.2010-0027)

[3. (Azoury2020Peptides) Marie Eliane Azoury, Mahmoud Tarayrah, Georgia Afonso, Aurore Pais, Maikel L. Colli, Claire Maillard, Cassandra Lavaud, Laure Alexandre-Heymann, Sergio Gonzalez-Duque, Yann Verdier, Joelle Vinh, Sheena Pinto, Soren Buus, Danièle Dubois-Laforgue, Etienne Larger, Jean-Paul Beressi, Graziella Bruno, Decio L. Eizirik, Sylvaine You, and Roberto Mallone. Peptides derived from insulin granule proteins are targeted by cd8+ t cells across mhc class i restrictions in humans and nod mice. Diabetes, 69(12):2678–2690, September 2020. URL: http://dx.doi.org/10.2337/db20-0013, doi:10.2337/db20-0013. This article has 35 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/db20-0013)

[4. (CorralPujol2023NOD) Marta Corral-Pujol, Berta Arpa, Estela Rosell-Mases, Leire Egia-Mendikute, Conchi Mora, Thomas Stratmann, Alex Sanchez, Anna Casanovas, Josep Enric Esquerda, Didac Mauricio, Marta Vives-Pi, and Joan Verdaguer. Nod mouse dorsal root ganglia display morphological and gene expression defects before and during autoimmune diabetes development. Frontiers in Endocrinology, June 2023. URL: http://dx.doi.org/10.3389/fendo.2023.1176566, doi:10.3389/fendo.2023.1176566. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2023.1176566)

[5. (Cassarino2018Gene) Maria Francesca Cassarino, Alberto G. Ambrogio, Andrea Cassarino, Maria Rosa Terreni, Davide Gentilini, Antonella Sesta, Francesco Cavagnini, Marco Losa, and Francesca Pecori Giraldi. Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles. Journal of Neuroendocrinology, August 2018. URL: http://dx.doi.org/10.1111/jne.12628, doi:10.1111/jne.12628. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jne.12628)

[6. (Farber2008Overexpression) Charles R Farber, James Chitwood, Sang-Nam Lee, Ricardo A Verdugo, Alma Islas-Trejo, Gonzalo Rincon, Iris Lindberg, and Juan F Medrano. Overexpression of scg5 increases enzymatic activity of pcsk2 and is inversely correlated with body weight in congenic mice. BMC Genetics, April 2008. URL: http://dx.doi.org/10.1186/1471-2156-9-34, doi:10.1186/1471-2156-9-34. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2156-9-34)

[7. (Kołat2022Prognostic) Damian Kołat, Żaneta Kałuzińska, Andrzej K. Bednarek, and Elżbieta Płuciennik. Prognostic significance of ap-2α/γ targets as cancer therapeutics. Scientific Reports, March 2022. URL: http://dx.doi.org/10.1038/s41598-022-09494-1, doi:10.1038/s41598-022-09494-1. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-09494-1)